E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Allergic (IgE-mediated) rhinitis / rhinoconjunctivitis triggered by house dust mites. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001725 |
E.1.2 | Term | Allergic rhinitis due to other allergen |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053713 |
E.1.2 | Term | Allergenic desensitisation procedure |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053741 |
E.1.2 | Term | Allergenic desensitization procedure |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001709 |
E.1.2 | Term | Allergic conjunctivitis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the study is to establish the maximum tolerated dose of PURETHAL Mites that is achieved by 90% of the patients with less than 20% of the injections giving rise to a swelling of > 5 cm and the optimal regimen to reach this maximum dose will be determined. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this trial are to monitor the safety of the injections and to measure short-term efficacy of the treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients with rhinitis or rhinoconjunctivitis, with or without mild asthma (FEV1 > 70%) for at least 2 years (their allergic symptoms must be related to HDM) • Positive CPT test to HDM Der p and Der f, dose ≤10,000 AUeq/ml • Positive SPT to HDM Der p and Der f (mean wheal diameter ≥ 3mm) • Specific serum IgE-test (ssIgE > 0.7 U/ml) for HDM • Age ≥ 18 years • Patients must give a written informed consent prior to inclusion
|
|
E.4 | Principal exclusion criteria |
• Concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3 mm) to other allergens than HDM, grass pollen, tree pollen or pets • Patients sensitized to grass pollen should not be starting treatment or evaluated during the period of grass pollen exposure • Patients sensitized to tree pollen should not be starting treatment or evaluated during the period of tree pollen exposure • Patients sensitized to both grass - and tree pollen • Patients sensitized to pets should not be included if they live together with these pets or have clinical symptoms • Immunotherapy (including sublingual) with HDM within the last 5 years • Immunotherapy (including sublingual) during the study period • Chronic asthma or emphysema, particularly with a FEV1 ≤ 70% of predicted value or use of inhalation corticosteroids • Serious immuno-pathologic diseases or malignancies (including auto-immune diseases, tuberculosis) • Symptomatic coronary heart diseases or severe (even under treatment) arterial hypertension • Diseases with a contra-indication for the use of adrenaline • Patients who are using other aluminium preparations, e.g. antacids • Severe kidney disease • Use of systemic steroids • Treatment with systemic and local ß-blockers or immunosuppressive drugs • Active infection of the target organs (nose or eyes) • Severe atopic dermatitis in case systemic immunosuppressive medication is used • Participation in a clinical study with a new investigational drug within the last 3 months • Pregnancy, lactation or inadequate contraceptive measures (adequate contraceptive measures will be the use of a contraceptive device or -pill) • Alcohol- or drug abuse • Lack of co-operation or severe psychological disorders • Institutionalisation by official or judical order
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Early local reactions (ELR) occurring 15 minutes after injection. Less than 20% of the injections should give rise to swelling at the injection site of >5cm in diameter occurring 15 minutes after injection.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |